nach oben

Erschienen in:

01.05.2006 | Original Article

Zygomycoses in patients with acute leukaemia

verfasst von: Enrico Schalk, Martin Mohren, Kathleen Jentsch-Ullrich, Frank Dombrowski, Astrid Franke, Michael Koenigsmann

Erschienen in: Annals of Hematology | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Zygomycoses are rare invasive mould infections which mainly occur in immunocompromised patients, especially during prolonged neutropenia. The high mortality rate is due to a high failure rate of both intravital diagnosis and treatment. Exact diagnosis requires microscopic examination and proof by culture. The treatment consists of amphotericin B and surgical debridement. We report four recent cases of zygomycosis among 89 patients with intensively treated acute leukaemia at our institution. Three cases were breakthrough infections since the patients were under voriconazole treatment prior to diagnosis of zygomycosis. Only one patient had premortal diagnosis (paranasal sinus infection) and showed clinical response with amphotericin B and surgical debridement. A review of the literature of these emerging fungal infections is given and is focused on patients with acute leukaemia. In addition, the importance of autopsy as a tool for quality control and epidemiological studies is pointed out.

Andresen D, Donaldson A, Chao L, Knox A, Klaassen M, Ursic C, Vonthethoff L, Krilis S, Konecny P (2005) Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 365:876–878CrossRefPubMed

Balasubramanian L, Trifilio SM, Tallman M, Mehta J, Bennett C (2005) Breakthrough zygomycoses in patients receiving antifungal therapy with voriconazole. J Clin Oncol 23(16S):601S (Abstract 6664)

Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S, Heussel G, Heussel CP, Junghanss C, Kern WK, Kubin T, Maschmeyer G, Sezer O, Silling G, Südhof T, Szelenyi H, Ullmann, AJ (2003) Treatment of fungal infections in hematology and oncology. Guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). Ann Hematol 82(suppl 2):S133–S140CrossRefPubMed

Chandrasekar P (2005) Riches usher dilemmas: antifungal therapy in invasive Aspergillosis. Biol Blood Marrow Transplant 11:77–84CrossRefPubMed

Doucette KE, Galbraith PA, Bow EJ, Binda BJ, Rendina A, Embil JM (2003) Disseminated zygomycosis: a rare cause of infection in patients with hematologic malignancies. J Trauma 55:568–570PubMedCrossRef

Gangat N, Khan MA, Mujib M, Khurshid M (2004) Pulmonary infiltrates during chemotherapy-induced febrile neutropenia: incidence, patterns and outcomes. J Pak Med Assoc 54:285–288PubMed

Ghannoum MA, Kuhn DM (2002) Voriconazole—better chances for patients with invasive mycoses. Eur J Med Res 7:242–256PubMed

Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ (2005) Inteferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 191:1180–1187CrossRefPubMed

Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N (2000) The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 117:279–282CrossRefPubMed

10.

Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E (2004) Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 45:1351–1360CrossRefPubMed

11.

Greenberg RN, Anstead G, Herbrecht R, Langston A, Marr K, Mullane K, Raad I, Schiller G, Schuster M, Van Burik J, Wingard JR, Hare R, Corcoran G (2003) Posaconazole (POS) experience in the treatment of zygomycosis. In: 43rd Interscience conference on antimicrobial agent and chemotherapy abstracts; Chicago, Illinois; 2003 Sept 14–17; Abstract M-1757. American Society for Microbiology, Washington, District of Columbia

12.

Greenberg RN, Scott LJ, Vaughn HH, Ribes JA (2004) Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 17:517–525CrossRefPubMed

13.

Herbrecht R (2004) Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 58:612–624CrossRefPubMed

14.

Imhof A, Balajee A, Fredricks DN, Englund JA, Marr KA (2004) Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39:743–746CrossRefPubMed

15.

Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, Thulkar S (2000) Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol 17:111–116CrossRefPubMed

16.

Jamadar DA, Kazerooni EA, Daly BD, White CS, Gross BH (1995) Pulmonary zygomycosis: CT appearance. J Comput Assist Tomogr 19:733–738CrossRefPubMed

17.

John BV, Chamilos G, Kontoyiannis DP (2005) Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 11:515–517CrossRefPubMed

18.

Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II (2005) Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observation study of 27 recent cases. J Infect Dis 191:1350–1360CrossRefPubMed

19.

Krcmery V Jr, Kunova E, Jesenska Z, Trupl J, Spanik S, Mardiak J, Studena M, Kukuckova E (1996) Invasive mold infections in cancer patients: 5 years’ experience with Aspergillus, Mucor, Fusarium and Acremonium infections. Support Care Cancer 4:39–45CrossRefPubMed

20.

Larkin JA, Montero JA (2003) Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 20:201–206

21.

Mantovani L, Hasenclever D, Krahl R, Pönisch W, Herold M, Pasold R, Fiedler F, Dölken G, Kämpfe D, Schmoll HJ, Subert R, Kubel M, Niederwieser D, Helbig W for the East German Hematology and Oncology Group (OSHO) (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I–II study. Leuk Lymphoma 43:265–274CrossRefPubMed

22.

Marty FM, Cosimi LA, Baden LR (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350:950–952CrossRefPubMed

23.

McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr (1997) Pulmonary mucormycosis: radiologic findings in 32 cases. Am J Roentgenol 168:1541–1548

24.

Mori T, Egashira M, Kawamata N, Oshimi K, Nakamura K, Oguri T, Aida H, Hiruma A, Ichinohe M (2003) Zygomycosis: two case reports and review of reported cases in the literature in Japan. Jpn J Med Mycol 44:163–179

25.

Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, Molteni A, Morra E (2000) Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 85:1068–1071PubMed

26.

Nosari A, Anghilieri M, Carrafiello G, Guffanti C, Marbello L, Montillo M, Muti G, Ribera S, Vanzulli A, Nichelatti M, Morra E (2003) Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica 88:1405–1409PubMed

27.

Oren I (2005) Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 40:770–771CrossRefPubMed

28.

Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, Cenacchi A, Pacilli L, Fabbiano F, Del Favero A (1997) Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematolgiche Malgine dell’Adulto). Br J Haematol 99:331–336CrossRefPubMed

29.

Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, Corvatta L, D’Antonio D, Girmenia C, Martino P, Del Favero A for the GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) Infection Program (2004) Mucormycosis in hematologic patients. Haematologica 89:207–214PubMed

30.

Pfaffenbach B, Donhuijsen K, Pahnke J, Bug R, Adamek RJ, Wegener M, Ricken D (1994) Systemic fungal infections in hematologic neoplasms. An autopsy study of 1,053 patients. Med Klin 89:299–304

31.

Prabhu RM, Patel R (2004) Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 10(suppl 1):31–47CrossRefPubMed

32.

Rickerts V, Böhme A, Just-Nubling G (2002) Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses 45(suppl 1):27–30PubMed

33.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653CrossRefPubMed

34.

Sammassimo S, Mazzotta S, Tozzi M, Gentili S, Lenoci M, Santopietro R, Bucalossi A, Bocchia M, Lauria F (2004) Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Enterococcus faecium. J Clin Microbiol 42:487–489CrossRefPubMed

35.

Sugar AM (2004) Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. Elsevier, Philadelphia, pp 2973–2984

36.

Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR (2002) In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 46:2310–2312CrossRefPubMed

37.

Tarrand JJ, Lichterfeld M, Warraich I, Luna M, Han XY, May GS, Kontoyiannis DP (2003) Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 119:854–858CrossRefPubMed

38.

Vigouroux S, Morin O, Moreau P, Mechinaud F, Morineau N, Mahe B, Chevallier P, Guillaume T, Dubruille V, Harousseau JL, Milpied N (2005) Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 40:e35–e37CrossRefPubMed

39.

Yeung CK, Cheng VCC, Lie AKW, Yuen KY (2001) Invasive disease due to mucorales: a case report and review of the literature. Hong Kong Med J 7:180–187PubMed

Titel: Zygomycoses in patients with acute leukaemia
verfasst von: Enrico Schalk
Martin Mohren
Kathleen Jentsch-Ullrich
Frank Dombrowski
Astrid Franke
Michael Koenigsmann
Publikationsdatum: 01.05.2006
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 5/2006
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-006-0082-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma

MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95

Mesenchymal stem cells feeder layer from human umbilical cord blood for ex vivo expanded growth and proliferation of hematopoietic progenitor cells

Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in a cohort of 1,000 neonates in Madrid (Spain)

Alterations of CD43 expression in transfusion-dependent myelodysplastic syndromes